moxifloxacin has been researched along with Bacteroides Infections in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (80.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Betriu, C; Culebras, E; Gómez, M; López, F; Picazo, JJ; Rodríguez-Avial, I | 1 |
| Hsueh, PR; Huang, YT; Liao, CH; Lin, HY; Liu, CY; Yen, LC | 1 |
| Ikebuchi, K; Imai, K; Kawamura, T; Kodana, M; Maeda, T; Maesaki, S; Mitsutake, K; Murakami, T; Ogane, K; Onodera, A; Sakai, J; Takeuchi, S; Tarumoto, N | 1 |
| Alder, JD; Citron, DM; Goldstein, EJ; Solomkin, JS | 1 |
| Goldstein, EJ | 1 |
| Ackermann, G; Beer, J; Blatz, R; Rodloff, AC; Schaumann, R | 1 |
| Chuah, SK; Gollapudi, S; Thadepalli, H | 1 |
| Hermsen, ED; Hovde, LB; Rodvold, KA; Rotschafer, JC; Sprandel, KA | 1 |
| Citron, DM; Fernandez, H; Goldstein, EJ; Merriam, CV; Tyrrell, KL; Warren, YA | 1 |
| Avlamis, A; Houhoula, DP; Katsandri, A; Legakis, NJ; Pantazatou, A; Papaparaskevas, J; Tsakris, A | 1 |
10 other study(ies) available for moxifloxacin and Bacteroides Infections
| Article | Year |
|---|---|
Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.
Topics: Anti-Bacterial Agents; Bacteroides; Bacteroides fragilis; Bacteroides Infections; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; Spain; Species Specificity; Time Factors | 2008 |
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; Bacteroides fragilis; Bacteroides Infections; Blood; Carbapenems; Cross Infection; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Taiwan | 2008 |
Antimicrobial susceptibility and prevalence of resistance genes in Bacteroides fragilis isolated from blood culture bottles in two tertiary care hospitals in Japan.
Topics: Ampicillin; Anti-Bacterial Agents; Bacterial Proteins; Bacteroides fragilis; Bacteroides Infections; beta-Lactamases; Blood Culture; DNA Transposable Elements; Doripenem; Drug Resistance, Multiple, Bacterial; Genes, Bacterial; Humans; Imipenem; Japan; Meropenem; Metronidazole; Microbial Sensitivity Tests; Moxifloxacin; Piperacillin, Tazobactam Drug Combination; Prevalence; Sulbactam; Tertiary Care Centers | 2020 |
Clinical efficacy and correlation of clinical outcomes with in vitro susceptibility for anaerobic bacteria in patients with complicated intra-abdominal infections treated with moxifloxacin.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteria, Anaerobic; Bacteroides Infections; Clostridium Infections; Fluoroquinolones; Humans; Intraabdominal Infections; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2011 |
Intra-abdominal anaerobic infections: bacteriology and therapeutic potential of newer antimicrobial carbapenem, fluoroquinolone, and desfluoroquinolone therapeutic agents.
Topics: Abdominal Abscess; Anti-Bacterial Agents; Aza Compounds; Bacteremia; Bacteria, Anaerobic; Bacteroides fragilis; Bacteroides Infections; beta-Lactams; Carbapenems; Clinical Trials as Topic; Ertapenem; Fluoroquinolones; Gemifloxacin; Humans; Indoles; Lactams; Moxifloxacin; Naphthyridines; Quinolines; Quinolones | 2002 |
Effect of moxifloxacin versus imipenem/cilastatin treatment on the mortality of mice infected intravenously with different strains of Bacteroides fragilis and Escherichia coli.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Bacteroides fragilis; Bacteroides Infections; Cilastatin; Cilastatin, Imipenem Drug Combination; DNA, Bacterial; Drug Combinations; Escherichia coli; Escherichia coli Infections; Female; Fluoroquinolones; Imipenem; Kidney; Liver; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Reverse Transcriptase Polymerase Chain Reaction | 2004 |
Therapeutic efficacy of moxifloxacin, a new quinolone, in the treatment of experimental intra-abdominal abscesses induced by Bacteroides fragilis in mice.
Topics: Abdominal Abscess; Animals; Anti-Bacterial Agents; Aza Compounds; Bacteroides fragilis; Bacteroides Infections; Clindamycin; Disease Models, Animal; Fluoroquinolones; Injections, Subcutaneous; Levofloxacin; Male; Metronidazole; Mice; Moxifloxacin; Ofloxacin; Quinolines | 2004 |
Levofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic model.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteroides fragilis; Bacteroides Infections; Chromatography, High Pressure Liquid; Colony Count, Microbial; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Half-Life; Humans; Levofloxacin; Metronidazole; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Ofloxacin; Quinolines | 2005 |
In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections.
Topics: Aza Compounds; Bacteroides fragilis; Bacteroides Infections; Fluoroquinolones; Gram-Negative Anaerobic Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Stomach Diseases | 2006 |
Moxifloxacin resistance is prevalent among Bacteroides and Prevotella species in Greece.
Topics: Adult; Anti-Bacterial Agents; Aza Compounds; Bacteroidaceae Infections; Bacteroides; Bacteroides Infections; Drug Resistance, Bacterial; Fluoroquinolones; Greece; Humans; Microbial Sensitivity Tests; Moxifloxacin; Prevotella; Quinolines | 2008 |